View in EDS

EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy.

Saved in:
Bibliographic Details
Title: EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy.
Authors: Ogino A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Vajdi A; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Mu XJ; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Mahadevan NR; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Ngo K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Booker MA; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Cejas P; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Center for Functional Cancer Epigenetics, and., Okoro JJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Xu M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Springer BF; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Eschle BK; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Messier CM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Wang S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Syamala S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Center for Functional Cancer Epigenetics, and., Tamen RM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Adeni AE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Chambers ES; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Canadas I; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Thai T; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Christensen CL; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Xu C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., Lizotte PH; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Oxnard GR; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Watanabe H; Catherine and Henry J. Gaisman Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine.; Tisch Cancer Institute; and.; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Center for Functional Cancer Epigenetics, and., Gokhale PC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science., Sholl LM; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Oser MG; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Barbie DA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Tolstorukov MY; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Source: JCI insight [JCI Insight] 2026 Jan 23; Vol. 11 (2). Date of Electronic Publication: 2026 Jan 23 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: eCollection Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41574603
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ogino+A%22">Ogino A</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Vajdi+A%22">Vajdi A</searchLink>; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Mu+XJ%22">Mu XJ</searchLink>; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Mahadevan+NR%22">Mahadevan NR</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Ngo+K%22">Ngo K</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.<br /><searchLink fieldCode="AU" term="%22Booker+MA%22">Booker MA</searchLink>; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Cejas+P%22">Cejas P</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Center for Functional Cancer Epigenetics, and.<br /><searchLink fieldCode="AU" term="%22Okoro+JJ%22">Okoro JJ</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Xu+M%22">Xu M</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.<br /><searchLink fieldCode="AU" term="%22Springer+BF%22">Springer BF</searchLink>; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Eschle+BK%22">Eschle BK</searchLink>; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Messier+CM%22">Messier CM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.<br /><searchLink fieldCode="AU" term="%22Wang+S%22">Wang S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.<br /><searchLink fieldCode="AU" term="%22Syamala+S%22">Syamala S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Center for Functional Cancer Epigenetics, and.<br /><searchLink fieldCode="AU" term="%22Tamen+RM%22">Tamen RM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Adeni+AE%22">Adeni AE</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Chambers+ES%22">Chambers ES</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Canadas+I%22">Canadas I</searchLink>; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Thai+T%22">Thai T</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Christensen+CL%22">Christensen CL</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Xu+C%22">Xu C</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Lizotte+PH%22">Lizotte PH</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.<br /><searchLink fieldCode="AU" term="%22Oxnard+GR%22">Oxnard GR</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Watanabe+H%22">Watanabe H</searchLink>; Catherine and Henry J. Gaisman Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine.; Tisch Cancer Institute; and.; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Long+HW%22">Long HW</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Center for Functional Cancer Epigenetics, and.<br /><searchLink fieldCode="AU" term="%22Gokhale+PC%22">Gokhale PC</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Paweletz+CP%22">Paweletz CP</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.<br /><searchLink fieldCode="AU" term="%22Sholl+LM%22">Sholl LM</searchLink>; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Oser+MG%22">Oser MG</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Barbie+DA%22">Barbie DA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Tolstorukov+MY%22">Tolstorukov MY</searchLink>; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Jänne+PA%22">Jänne PA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.; Belfer Center for Applied Cancer Science.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101676073%22">JCI insight</searchLink> [JCI Insight] 2026 Jan 23; Vol. 11 (2). <i>Date of Electronic Publication: </i>2026 Jan 23 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+for+Clinical+Investigation%22">American Society for Clinical Investigation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101676073 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2379-3708 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223793708%22">23793708 </searchLink><i>NLM ISO Abbreviation: </i>JCI Insight <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41574603
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1172/jci.insight.197008
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: EGFR-mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ogino A
      – PersonEntity:
          Name:
            NameFull: Vajdi A
      – PersonEntity:
          Name:
            NameFull: Mu XJ
      – PersonEntity:
          Name:
            NameFull: Mahadevan NR
      – PersonEntity:
          Name:
            NameFull: Ngo K
      – PersonEntity:
          Name:
            NameFull: Booker MA
      – PersonEntity:
          Name:
            NameFull: Cejas P
      – PersonEntity:
          Name:
            NameFull: Okoro JJ
      – PersonEntity:
          Name:
            NameFull: Xu M
      – PersonEntity:
          Name:
            NameFull: Springer BF
      – PersonEntity:
          Name:
            NameFull: Eschle BK
      – PersonEntity:
          Name:
            NameFull: Messier CM
      – PersonEntity:
          Name:
            NameFull: Wang S
      – PersonEntity:
          Name:
            NameFull: Syamala S
      – PersonEntity:
          Name:
            NameFull: Tamen RM
      – PersonEntity:
          Name:
            NameFull: Adeni AE
      – PersonEntity:
          Name:
            NameFull: Chambers ES
      – PersonEntity:
          Name:
            NameFull: Canadas I
      – PersonEntity:
          Name:
            NameFull: Thai T
      – PersonEntity:
          Name:
            NameFull: Christensen CL
      – PersonEntity:
          Name:
            NameFull: Xu C
      – PersonEntity:
          Name:
            NameFull: Lizotte PH
      – PersonEntity:
          Name:
            NameFull: Oxnard GR
      – PersonEntity:
          Name:
            NameFull: Watanabe H
      – PersonEntity:
          Name:
            NameFull: Long HW
      – PersonEntity:
          Name:
            NameFull: Gokhale PC
      – PersonEntity:
          Name:
            NameFull: Paweletz CP
      – PersonEntity:
          Name:
            NameFull: Sholl LM
      – PersonEntity:
          Name:
            NameFull: Oser MG
      – PersonEntity:
          Name:
            NameFull: Barbie DA
      – PersonEntity:
          Name:
            NameFull: Tolstorukov MY
      – PersonEntity:
          Name:
            NameFull: Jänne PA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 01
              Text: 2026 Jan 23
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2379-3708
          Numbering:
            – Type: volume
              Value: 11
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: JCI insight
              Type: main
ResultId 1